Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection
Authors:
Open Access
- 21 April 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1828887
Abstract
The continuous evolution of SARS-CoV-2 poses a significant challenge to existing immune barriers, highlighting the limitations of single-modality immunization. Hybrid immunity, shaped by the combination of natural infection and vaccination, induces more potent, broad-spectrum, and durable protective immunity. This review proposes that heterologous vaccination – the sequential use of vaccines based on different technological platforms – can serve as an active public health strategy to simulate and optimize hybrid immunity. We systematically elaborate on the synergistic advantages of hybrid immunity at both the humoral and cellular levels, citing evidence from multiple clinical trials that for both convalescent individuals and infection-naïve populations, heterologous vaccination regimens outperform homologous regimens in enhancing the breadth of neutralizing antibodies, strengthening cross-protection, and establishing robust immune memory. By mimicking the antigenic distance effect, heterologous vaccination safely replicates the immunological benefits of natural infection without the associated risks, positioning it as a key strategic tool to counter persistent viral evolution and build a resilient population-wide immune barrier.Keywords
This publication has 32 references indexed in Scilit:
- Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patternsVaccine, 2025
- Safety, immunogenicity, and breakthrough infection of nine homologous or heterologous COVID-19 vaccination booster regimens in healthy adults: A prospective study in TaiwanVaccine, 2025
- First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialEBioMedicine, 2024
- Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trialVaccine, 2024
- Rational design of a booster vaccine against COVID-19 based on antigenic distanceCell Host & Microbe, 2023
- Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responsesCell, 2022
- Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trialJournal of Infection, 2022
- Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunityCell, 2022
- Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccinationCell, 2022
- Antibody and B cell responses to SARS-CoV-2 infection and vaccinationCell Host & Microbe, 2021